Compare Gartner Inc (IT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gartner Inc vs BIO-TECHNE Corp — how do they compare? Gartner Inc trades at $188.05 (market cap $12.20B), while BIO-TECHNE Corp trades at $72.04 (market cap $11.24B). The key difference: Gartner Inc and BIO-TECHNE Corp are close in size by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Gartner Inc pays none. Which is the better fit depends on your goals.
| IT | TECH | |
|---|---|---|
Market Cap | $12.20B | $11.24B |
Sector | Technology | Health |
52-Week High | $264.09 | $72.29 |
52-Week Low | $125.68 | $43.31 |
Enterprise Value | $13.94B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gartner (IT) trades at $185.6, up 0.42% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with a 69.63% gross margin and 12% net income margin, though revenue growth has moderated. Recent news highlights Q2 2026 earnings exceeding expectations and raised full-year EPS guidance, driving positive investor sentiment.
Outlook is supported by valuation discounts (P/E 16.69) and high ROE (113.58%), but risks include consulting segment weakness and negative net cash flow trends. Analysts are mixed with a $172.80 consensus target, suggesting cautious optimism amid execution challenges.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
